New Approaches to Joint Repair for Osteoarthritis Patients

Duke-led team advances therapies that aim to regenerate damaged joints and treat the root cause of the disease

Man in white doctor coat (Dr. Benjamin Alman) sits smiling at the camera with out of focus clinical equipment in the background.

The following is a summary of a press release on Duke Health.

For millions living with osteoarthritis, treatment manages pain but doesn’t fix the problem. The disease affects more than 32 million Americans and often leads to injections or joint replacement surgery. A Duke-led research team is working toward a different approach.

Instead of treating symptoms, their goal is to help the body repair damaged joints at the source. The work developing three experimental treatments is showing positive results in preclinical studies.

In animal models, these therapies were able to restore joint tissue to near-normal levels and reduce pain markers over time. While the treatments have not yet been tested in humans, the results suggest a new way to target the underlying damage that causes pain and loss of function, rather than just managing its effects.

“This milestone brings us closer to a future where we can treat the root cause of osteoarthritis, not just the symptoms,” said project lead Dr. Benjamin A. Alman, chair of orthopaedic surgery at Duke University School of Medicine.

The project is part of a national, federally funded effort focused on regenerative medicine, bringing together researchers from UCLA, Boston Children's Hospital, and Harvard University. Together, they are developing treatments designed to activate the body’s natural repair systems in cartilage and bone, the tissues that deteriorate in osteoarthritis.

“This is where the science must meet the highest standards,” Alman said. “Every step now is about safety, rigor, and doing this the right way.”

The next phase will focus on safety testing, dosing, and preparing for regulatory approval before clinical trials can begin. If progress continues, researchers expect to begin testing in humans within the next 18 to 24 months. They have filed patent applications and are planning a startup to help bring these potential therapies to market.

“Our goal is simple,” Alman said. “To give people with osteoarthritis a chance to keep moving, stay active and avoid surgery whenever possible.”

Learn more about how federally funded Duke Research Saves Lives in the full press release on Duke Health.